Novartis to acquire Avidity Biosciences for about $12 billion
By Padmanabhan Ananthan and Angela Christy M (Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash, as the company looks to bolster its portfolio of treatments for rare muscle disorders. As per the terms of the deal, Avidity stockholders will receive $72
Continue Reading